Eradicate Cancer

New development for Lung Cancer patients with EGFR mutation

Osimertinib Improves Progression-Free Survival for EGFR -Positive NSCLC in the Phase III FLAURA Trial - The ASCO Post On July 27, it was announced that the phase III FLAURA trial showed a statistically significant and clinically meaningful progression-free survival benefit with osimertinib (Tagrisso) compared to current first-line standard-of-care treatment (erlotinib [Tarceva] or gefitinib [Iressa]) in previously…

Another milestone in the immunotherapeutics. New and safer treatment for newly diagnosed Lung Cancer patients.

FDA Approves Pembrolizumab as First-Line Treatment for PD-L1–Positive Non–Small Cell Lung Cancer - The ASCO Post On October 24, 2016, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) for the treatment of patients with metastatic non–small cell lung cancer (NSCLC) whose tumors express programmed cell death ligand 1 (PD-L1) as determined by an FDA-approved test.